Colorado大學(xué)Denver健康科學(xué)中心(UCDHSC, Denver, CO, USA)和Source MDx (Boulder, CO, USA)已經(jīng)達成了一項研究合作計劃，開發(fā)皮膚疾病早期診斷和預(yù)后的分子學(xué)診斷方法，包括黑色素瘤和牛皮癬。

惡性黑色素瘤進展迅速危及生命的皮膚癌，極易轉(zhuǎn)移至身體其他部位。Mayumi Fujita博士是Colorado大學(xué)醫(yī)學(xué)院皮膚科的助理教授，他說：“黑色素瘤早期診斷和準確分級是治療的關(guān)鍵，將會發(fā)生轉(zhuǎn)移的患者鑒別出來，是對指導(dǎo)制定治療方案是十分重要的，惡性黑色素瘤在轉(zhuǎn)移之前是能夠治療的疾病。”

Collaboration to Develop Molecular Tests for Skin Diseases
 
The University of Colorado at Denver Health Sciences Center (UCDHSC, Denver, CO, USA) and Source MDx (Boulder, CO, USA) have entered into a research collaboration to develop molecular diagnostic tests for early diagnosis and prognosis of skin diseases, including melanoma and psoriasis.

Malignant melanoma is the most aggressive and life-threatening skin cancer and has a high tendency to spread to other parts of the body. “Early detection and accurate staging of melanoma is critical to the management of melanoma, and identifying the patients who will show progression to metastatic disease is important to direct an appropriate treatment regimen,” said Mayumi Fujita, M.D., Ph.D., assistant professor in the department of dermatology at the University of Colorado School of Medicine. “Malignant melanoma, when detected prior to progression, is a highly curable malignancy.”